Merck Starts Phase 1 Trial of Oral Peptide Developed With Cyprumed's Technology
MT Newswires Live
Sep 29
Merck (MRK) has initiated a phase 1 clinical trial of an oral peptide drug candidate that was formulated using Cyprumed's oral tablet technology, Cyprumed said Tuesday.
The trial is covered under the companies' April 2025 non-exclusive license and option deal that allows Merck to develop oral peptide formulations using Cyprumed's drug delivery technology, according to the statement. Cyprumed said the deal entitles it to upfront and milestone payments of up to $493 million.
No other trial details were disclosed. Cyprumed said the trial triggers a payment under the agreement with Merck, without disclosing the specific amount.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.